The effectiveness of anticonvulsants in psychiatric disorders by Grunze, Heinz C. R.
t is virtually impossible to draw a clear divid-
ing line between neurology and psychiatry,as many neu-
rological disorders,including epilepsy,also have a strong
component of behavioral impairment. On the other
hand,disorders such as dementia that are primarily cog-
nitive and behavioral involve massive neuroanatomical
and neurofunctional changes.Research into this psychi-
atry/neurology interface—neuropsychiatry—attracts
participants from many disciplines, as disorders thus
described may help understanding of how neu-
roanatomical or neurochemical underpinnings can be
expressed in (aberrant) behavior. Medications used in
these neuropsychiatric disorders usually focus on symp-
toms.As in the case of anticonvulsants,they may not act
purely on a neurological phenomenon,such as prevent-
ing or terminating a full seizure,but,due to the close link
between epilepsy and emotional and behavioral brain
functions,also on areas such as mood regulation,or fear
and anxiety.Whereas negative effects on mood and anx-
iety states have been described quite frequently with the
first generation of antiepileptic drugs, especially
bromium and later barbiturates,it was in the 1960s that
the first observations describing positive and mood-sta-
bilizing effects of anticonvulsant drugs (ACs) were pub-
lished.In 1967 Turner published an observational study
entitled “The usefulness of diphenylhydantoin in treat-
ment of non-epileptic emotional disorder,”
1 separating
for the first time the mood effects of antiepileptic drugs
from their antiepileptic efficacy.At the same time, or
soon afterwards, the first reports on the mood-stabiliz-
ing efficacy of carbamazepine
2 and valpromide
3 were
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Anticonvulsant drugs are widely used in psychiatric indi-
cations. These include mainly alcohol and benzodi-
azepine withdrawal syndromes, panic and anxiety dis-
orders, dementia, schizophrenia, affective disorders,
bipolar affective disorders in particular, and, to some
extent, personality disorders. A further area in which
neurology and psychiatry overlap is pain conditions, in
which some anticonvulsants, and also typical psychiatric
medications such as antidepressants, are helpful. From
the beginning of their psychiatric use, anticonvulsants
have also been used to ameliorate specific symptoms of
psychiatric disorders independently of their causality and
underlying illness, eg, aggression, and, more recently,
cognitive impairment, as seen in affective disorders and
schizophrenia. With new anticonvulsants currently under
development, it is likely that their use in psychiatry will
further increase, and that psychiatrists need to learn
about their differential efficacy and safety profiles to the
same extent as do neurologists.     
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proven or potential usefulness in treating mood-disor-
dered patients in particular is quite respectable. More
recently, newly developed ACs have also been tested
more rigorously in anxiety states, to the point where
some of the newer ACs are now more frequently used in
treating anxiety than epilepsy.Finally,as ACs act against
a state of neuronal hyperexcitability,it was obvious that
they should be tested in other conditions thought to be
caused by aberrant excitability,such as substance abuse
and withdrawal and pain conditions, the latter also
including a strong negative affective component.This
article aims to provide a condensed overview of the pro-
posed mechanisms of action and effectiveness of older
and newer ACs by looking at various psychiatric disor-
ders or syndromes. Table I supplies an overview of the
candidate ACs for psychiatric indications, and the level
of evidence for their use.
Although safety and tolerability are aspects of utmost
importance,they will not be dealt with in this article for
the sake of comprehensiveness.However,it is strongly
recommended that readers educate themselves about the
individual safety issues of ACs before applying them in
routine practice.Recent reviews (eg,refs 4-7) are a com-
prehensive source of information for further reading.
Mechanisms of action beyond 
antiepileptic properties
A common link between the different indications where
ACs are used may be an underlying state of hyperex-
citability which may manifest itself as sleep disturbances,
mood swings,anger,or impulsiveness.There are several
hypotheses about a common underlying pathophysiol-
ogy,but excessive sodium and calcium fluxes may play
a role both in epilepsy and the abovementioned psychi-
atric conditions.Several anticonvulsants,including car-
bamazepine,valproate,lamotrogine,and phenytoin,have
a regulating effect on these ion fluxes,
8 and this may
explain part of their efficacy in some psychiatric disor-
ders such as withdrawal states, pain, or, as a state of
behavioral hyperactivity,acute mania.
9,10Antidepressant
effects may also be explainable,at least in part,through
modulation of serotonin (valproate and lamotrigine
11-13),
dopamine (valproate
11),noradrenalin (lamotrigine
14) and
hypothalamic-pituitary activity (lamotrigine
15).For the
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Table I. Evidence from monotherapy and add-on studies for the efficacy of anticonvulsants in psychiatric and neuropsychiatric disorders. Evidence:
+++, evidence from at least two randomized, placebo-controlled studies; ++, evidence from one placebo-controlled study or at least two
randomized comparator studies or a systematic metaanalysis; +, evidence from only one comparator study, open studies; 0, not tested (or
no published results); -, negative evidence. GAD, generalized anxiety disorder; PD, panic disorder; SP, social phobia; PTSD, post-traumatic
stress disorder; MDD, (a)= major depressive disorder (= unipolar depression), acute treatment; MDD, (p)= major depressive disorder (= unipo-
lar depression), prophylactic treatment; BPm, bipolar disorder, manic; BPd = Bipolar disorder, depressed; BPp =Bipolar disorder, prophylaxis;
BPD, borderline personality disorder; PHN, postherpetic neuralgia
Indication
Anxiety disorders Affective disorders Schizophrenia BPD Neuropathic Other pain 
pain conditions
Anticonvulsant GAD PD SP PTSD MDD MDD BPm BPd BPp PHN,  DPN Migraine, 
(a) (p) trigeminal 
neuralgia
Carbamazepine 0 - 0 + + + +++ + ++ ++ ++ + +++
Valproate 0 ++ 0 + + 0 +++ + ++ ++ + + +++
Lamotrigine 0 0 0 ++ ++ 0 ++ - +++ +++ + - +
Phenytoin 0 0 0 + + 0 ++ - ++ 0 0 ++ + (fosphenytoin)
Oxcarbazepine 0 0 0 + + + ++ + + + + ++ ++
Gabapentin 0 ++ ++ + 0 0 - + ++ 0 0 +++ +
Pregabalin +++ 0 ++ 0 0 0 0 0 0 0 0 +++ +++
Vigabatrin 0 0 0 0 0 0 0 0 0 0 0 0 0
Topiramate 0 0 0 ++ ++ 0 - + 0 ++ +++ - +++
Tiagabine - 0 0 0 0 0 - 0 0 0 0 0 0
Levetiracetam 0 0 0 0 0 0 + + 0 0 0 0 0
Zonisamide 0 0 0 0 0 0 + + 0 0 0 0 0treatment of anxiety states, the γ-aminobutyric acid
(GABA)ergic action of some anticonvulsants,eg,prega-
balin and gabapentin,may be more decisive.
16 However,
these acute receptor-transmitted effects are largely insuf-
ficient to explain, eg, long-term stabilization of mood
such as that provided by lithium.During the last decade,
it has been demonstrated that not only lithium,but also
valproate and,in part,carbamazepine,regulate numer-
ous factors enhancing cellular plasticity and resilience,
including inositol biosynthesis (MIP synthase), cyclic
adenosine monophosphate (c-AMP) response element
binding protein, brain-derived neurotrophic factor
(BDNF),the extracellular signal-regulated kinase path-
way, the arachidonic acid pathway, the cytoprotective
protein bcl-2 and mitogen-activated protein kinases.
17-24
All these intracellular actions may contribute to pre-
venting a kindling process which otherwise leads to a
constant decline of the threshold for relapses.The amyg-
dala kindling model,originally developed to explain pro-
gression of epileptic seizures,
25 may also be applicable to
affective episodes, panic attacks and anxiety states, or
alcohol and drug relapses.
26
Substance abuse
Alcohol
Although their mechanism of action is not completely
understood,the efficacy of anticonvulsants in the alcohol
withdrawal syndrome is thought to be related to their
ability to inhibit kindling and facilitate GABA inhibitory
neurotransmission.A recent Cochrane meta-analysis of
48 studies involving 3610 subjects compared different
ACs with placebo for alcohol withdrawal,Therapeutic
success tended to be more common among the anticon-
vulsant-treated patients (relative risk (RR) 1.32; 95%
confidence interval (CI) 0.92 to 1.91),and ACs tended to
show a protective benefit against seizures (RR 0.57;95%
CI 0.27 to 1.19),but no effect reached formal statistical
significance.
27 Nevertheless,there is limited positive evi-
dence for some ACs. Carbamazepine
28 and oxcar-
bazepine
29 alone or,especially in Germany,in combina-
tion with tiapride,
30 are frequently used for alcohol
withdrawal because they reduce the risk of convulsions
and,especially in the case of carbamazepine,cause an ini-
tial sedation when titrated rapidly. For oxcarbazepine,
open data also suggest anticraving effects in sober alco-
holics.
31 There are also some reports on the use of val-
proate for alcohol withdrawal. Myrick et al
32 reported
comparable effects of lorazepam and valproate in reduc-
ing alcohol withdrawal symptoms in an open trial.In a
double-blind randomized study,Tress et al
33 compared
valproate with clomethiazol,observing no difference in
somatic symptoms and the absence of severe delirious
states with both medication.The so-far largest controlled
study using valproate for alcohol withdrawal syndromes
was conducted by Hillbom et al
34 comparing valproate
with carbamazepine and placebo.The reduction of with-
drawal seizures was more pronounced with valproate
(2.2% vs 4.7% with carbamazepine and 6.1% with
placebo).However,there was also a higher,but not sig-
nificant, rate of delirium (valproate 4.4%). compared
with 2.2% for placebo and none with carbamazepine.The
authors also report a better general tolerability of val-
proate compared with carbamazepine. In conclusion,
there is some evidence for effectiveness not only of car-
bamazepine,but also of valproate in uncomplicated alco-
hol withdrawal,but it is obvious that better controlled
studies are needed.So far,of all the anticonvulsants only
carbamazepine reached such a level of confidence that it
has been recommended in guidelines as suitable for the
pharmacological management of alcohol withdrawal.
35
Newer antiepileptic drugs that had been tested in open-
case series in the indication of alcohol withdrawal have
produced conflicting results,eg,gabapentin,vigabatrin
and topiramate
36-38; however, randomized studies are
missing or negative.
39
Valproate and lamotrigine have also been tested in con-
trolled studies in bipolar patients with comorbid alcohol
abuse for their effects on drinking habits.For valproate,
a significant reduction in heavy drinking days was found
in a controlled study,
40 and also lamotrigine reduced alco-
hol intake and craving in an open study.
41There are also
some case series on carbamazepine and lamotrigine low-
ering alcohol consumption in comorbid schizophrenia
and alcohol dependence.
42,43
Cocaine dependence
As there is a high comorbidity,especially between bipo-
lar disorder and cocaine dependence,some mood-stabi-
lizing anticonvulsants have been tested in terms of their
utility in limiting drug abuse.Both valproate
44 and lam-
otrigine
45 demonstrated mood-stabilizing effects in open-
label trials,and some positive effects on drug abuse,such
as diminished consumption (valproate) and less craving
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79(lamotrigine).In a small placebo-controlled pilot trial,
topiramate also proved effective in attaining at least 3
weeks of continuous abstinence.
46 However,more con-
trolled evidence still needs to be collected.
Sedatives and tranquilizer abuse
A potential role for GABA uptake inhibitors such as
tiagabine for benzodiazepine withdrawal has been sug-
gested,
47 but never been rigorously tested.Of the older
anticonvulsants,valproate has been tested in open case
series,
48 and has been compared against trazodone and
placebo for benzodiazepine withdrawal. Rickels et al
49
reported that more patients were free of benzodiazepines
after 5 weeks when treated with valproate or trazodone
compared with placebo.However,they did not find a sig-
nificant reduction of somatic symptoms during benzodi-
azepine tapering.According to a Cochrane meta-analy-
sis of available trials, carbamazepine shows a rather
modest benefit in reducing withdrawal severity, but it
does significantly improve drug-free outcome.
50 However,
a note of caution should be used when using carba-
mazepine (and oxcarbazepine) in withdrawal states.
Patients’ predisposition to hyponatremia and consecu-
tive seizures despite anticonvulsant treatment may be
increased.
51 Other newer substances,eg,gabapentin and
topiramate, show promise from case studies; however,
randomized studies are still lacking.
28,52
Smoking cessation
A very recent field with potential usefulness of some 
new anticonvulsants is smoking cessation. Due to 2-
(aminomethyl)phenylacetic acid AMPA/kainate antago-
nism,topiramate has been assumed to be a potential can-
didate medication.A small open study by Khazaal et al
53
supports this assumption;however,in briefly abstinent
smokers topiramate may also enhance withdrawal and
rewarding effects when relapsing,thus calling into ques-
tion its usefulness.
54
Anxiety disorders and post-traumatic 
stress disorder (PTSD)
A broad area for the use of antiepileptic drugs in psy-
chiatry is anxiety disorders,especially generalized anxi-
ety (GAD), social phobia and panic attacks, as well as
post-traumatic stress disorder (PTSD). This area has
been most recently comprehensively reviewed by Mula
et al.
16 Repetitive activation and kindling of brain struc-
tures involved in fear responses, such as the amygdala
and the hippocampus,may result in an inadequate,exci-
tatory output,similar to that observed in epilepsy.Thus,
ACs could be of potential value by limiting this excessive
activation.Open studies provide some limited evidence
for the usefulness of carbamazepine in PTSD,
55-57 whereas
for other anxiety syndromes the evidence is vague or
negative (eg,for panic disorder
58).For valproate,one con-
trolled study and several open studies reported efficacy
in panic disorder alone or when accompanied by mood
symptoms.
59 Lum
60 compared valproate with placebo for
6 weeks.He observed a significant reduction in the inten-
sity and the duration of panic attacks. However, this
study is clearly limited by the small number of patients
(n=12).Also of interest is an open study by Keck.
61 In
patients with a history of panic attacks, panic attacks
were induced by lactate infusions.After treatment with
valproate for 1 month,almost half of the patients were
free of spontaneous panic attacks, and 10 out of 12
patients tested no longer developed panic attacks pro-
voked by lactate infusions.For other anxiety syndromes
and PTSD,evidence is again restricted to open-label tri-
als (eg,ref 62) and case series.
Moderate evidence stemming from a small, but con-
trolled study exists for the use of lamotrigine in PTSD
63;
however,no proper-sized randomized studies have been
conducted so far.Another double-blind, placebo-con-
trolled trial assessed efficacy and safety of topiramate
monotherapy in civilian posttraumatic stress disorder and
found evidence supporting topiramate’s efficacy.
64The
GABA transporter inhibitor tiagabine and GABA
transaminase blocker vigabatrine, which theoretically
should be useful in anxiety states,
65 were either not tested
in controlled studies (vigabatrine) or could not fulfil the
promises of open studies in a randomized placebo-con-
trolled study of GAD (tiagabine
66).
This situation is different for two other antidepressants,
gabapentin and pregabalin.For gabapentin,two double-
blind placebo-controlled studies showed positive results
in panic disorder and social phobia.
67,68 Even more com-
pelling is the evidence for pregabalin.Five positive dou-
ble-blind,placebo-controlled studies in GAD
69-73 and one
positive controlled study in social phobia
74 make this
compound indeed a well-proven anxiolytic medication.
For GAD,an optimal dosage of 200 to 450 mg /day had
been determined.
75
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Following up on earlier observations that antiepileptic
drugs reduce aggressiveness in behaviorally disturbed
epileptic patients,several antiepileptic drugs were also
tested in demented patients with destructive behavior.
After several case reports showed efficacy on aggres-
siveness with valproate, a recent review article by
Lindenmayer
76 analyzed these case reports of violent and
aggressive demented patients and found an overall
response rate of 77.1%, defined as an at least 50%
improvement on the applied scale for aggressiveness.
However,a combined analysis of four small controlled
studies could not support valproate’s efficacy.
77 Case
reports also suggested beneficial effects of lamotrigine,
78
gabapentin,
79 and levetiracetam
80 in agitated and aggres-
sive demented patients, but, as with other indications
there is still an obvious need for more controlled studies.
Pain
Many neurologists might object to a section on pain as a
psychiatric condition.However,most types of pain cannot
be conceptualized as a pure neurological dysfunction,but
also involve strong subjective and emotional aspects.The
exact mechanisms of how ACs work in pain conditions are
far from being understood;however,it is intuitive that they
may be able to dampen many of the proposed causes of
chronic pain,such as peripheral sensitization,central sen-
sitization,wind-up,hyperexcitability,neuronal disinhibition,
ectopic impulse formation, and finally, the subjective
impression and emotional handling of pain.For example,
abnormal activation of the NMDA receptor is believed to
be an integral part of kindling in epilepsy as well as wind-
up in neuropathic pain;consequently,pharmacologic agents
that suppress this excitation may explain their utility in
both conditions.
81 In addition,as already detailed in the sec-
tion on neurobiology,several ACs also have intrinsic,anti-
depressant–like effects on serotonin and noradrenalin,eg,
the long known activating effect of carbamazepine on locus
coeruleus neurons,
82 the postsynaptic serotonin (5-HT)1A
receptor activity of lamotrigine in the forced swimming
test,
83 the presynaptic enhancement of serotonin transmis-
sion by valproate via a subsensitization of 5-HT1A autore-
ceptors,
84 and theories about the close linkage between
depression and epilepsy have been evolved.
85 Given the
efficacy of several antidepressants in pain conditions,these
effects may be helpful for the subjective side of pain.
Not all ACs appear to be as effective as antidepressants
(tricyclics and noradrenalin and serotonin reuptake
inhibitors) in treating pain syndromes,
86 but at least
gabapentin and pregablin can be recommended,among
other medications,as first-line treatment for neuropathic
pain
87,88 and related conditions.Both medications are also
licensed for the treatment of neuropathic pain,based on
a large portfolio of controlled studies.
Relief from pain has been greater with gabapentin than
with placebo in controlled studies of postherpetic neu-
ralgia (PHN), painful diabetic polyneuropathy (DPN),
phantom limb pain,diverse peripheral neuropathic pain
conditions,Guillain-Barré syndrome,neuropathic cancer
pain, and acute and chronic spinal cord injury pain.
89-98
The effective dosage in these studies was usually
between 1800 and 3600 mg/day. In addition, several of
these studies described positive effects on mood and
sleep quality.
Pregabalin has demonstrated efficacy in seven controlled
studies in PHN,DPN,or either of these conditions
99-105A
randomized controlled trial in patients with spinal cord
injury neuropathic pain also demonstrated greater pain
relief with pregabalin than with placebo.
106 Maximum
benefits typically occurred after 2 weeks of treatment at
target dosages of 300 to 600 mg/day.
In contrast to their established efficacy in trigeminal neu-
ralgia,
107,108 carbamazepine and oxcarbazepine have
yielded inconsistent results in controlled studies of other
types of neuropathic pain.
86These studies have generally
had limited methodological quality.
Three positive trials of valproate in DPN or PHN were
reported from a single center,but a controlled study con-
ducted in patients with painful polyneuropathies by a dif-
ferent research group was negative.
109 In migraine pro-
phylaxis,however,several studies,including a Cochrane
meta-analysis,clearly support the efficacy of valproate.
110
In a number of relatively small randomized studies,lam-
otrigine showed evidence of efficacy in several types of
neuropathic pain or in subgroups of patients with these
conditions. However, intention-to-treat analyses were
negative in three large recent randomized controlled
studies,two of which were in painful DPN
111 and one in
neuropathic pain of different origin.
112
In patients with painful DPN,topiramate showed efficacy
in one RCT but not in three others,and its efficacy was
equivocal in a trial of chronic lumbar radicular pain.
87 In
migraine,at least five controlled studies now support the
efficacy of topiramate.
113-117
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Although not licensed in this indication, antiepileptic
drugs,especially carbamazepine and valproate,are also
widely used in schizophrenic patients who do not
improve sufficiently on neuroleptic medications. This
may be the case in up to 20% of all schizophrenic
patients.
118 GABAergic drugs,such as valproate or car-
bamazepine, may decrease the dopaminergic drive by
acting on the mesoprefrontal dopamine tract.
Consecutively, Simhandl et al
119 reported a significant
effect in chronic schizophrenia for adjunctive carba-
mazepine treatment in an 8-week double-blind,placebo-
controlled study. However, the use of carbamazepine
may also diminish serum levels of some antipsychotics,
eg,risperidone or haloperidol,and thus lead to worsen-
ing of psychosis.
120A recent Cochrane meta-analysis also
came to the conclusion that carbamazepine cannot be
recommended for routine clinical use for the treatment
of augmentation of antipsychotic treatment of schizo-
phrenia.
121
The widespread use of valproate—especially in the US—
in schizophrenic patients is backed up by at least 6 open
positive studies including difficult-to-treat late-life schiz-
ophrenia,
122 and two double-blind add-on studies.
123,124A
meta-analysis including all randomized studies,however,
again gave no unambiguous evidence in favor of val-
proate.
125
The antiglutamatergic actions of lamotrigine and topira-
mate may be of particular interest because of hypothe-
sized glutamatergic mechanisms in schizophrenia.They
may be capable of reducing excessive glutamatergic
hyperactivity due to selective NMDA receptor blockade
of interneurons.
126A well-controlled experimental study
observed protective effects of lamotrigine against keta-
mine-induced psychosis
127 followed by three blinded,
placebo-controlled studies in which lamotrigine was
shown to be effective (in combination with clozapine or
other atypical antipsychotics) in treatment-refractory
schizophrenic patients.
128-130 However,again,a meta-analy-
sis including all randomized studies was not able to sup-
port lamotrigine’s effectiveness,mostly due to the poor
quality of reporting of every single trial.
131 For topira-
mate,a small (n=26) but placebo-controlled add-on study
of ongoing atypical antipsychotics was suggestive of
effects on general psychopathology, but was unable to
show a significant improvement in positive or negative
symptoms.
132
Affective disorders
Unipolar depression
Although large randomized, placebo-controlled
monotherapy trials failed,
133 lamotrigine may be of
interest for the treatment of refractory unipolar depres-
sion. Retrospective chart reviews (eg, ref 134) open
135
and randomized open-label,
136 and controlled augmen-
tation studies
137,138 are supportive of an antidepressant
effect of lamotrigine add-on in treatment-resistant
major depressive disorder (MDD).
In a double-blind,placebo-controlled study,topiramate
appeared to be an effective agent in the reduction of
depressive symptoms and anger in moderately depressed
women,
139 but these results have not yet been replicated.
Of the older anticonvulsants,carbamazepine has shown
limited evidence in open studies for an acute antidepres-
sant
140-143 and prophylactic effect.
144Valproate may be effec-
tive in major depression as demonstrated by an open
trial,
145 especially when agitation is a prominent symp-
tom,
146 but conclusive controlled studies are missing.
Phenytoin showed some efficacy in a comparator study
against fluoxetine,
147 but not in an augmentation study in
SSRI nonresponders.
148
Bipolar disorder
The classical psychiatric indication for antiepileptic drugs
is clearly bipolar disorder.Licensed in this indication or at
least used with good evidence are valproate, carba-
mazepine,and lamotrigine,but phenytoin,oxcarbazepine,
levetiracetam, topiramate, zonisamide, and gabapentin
may also be beneficial in some,yet insufficiently charac-
terized patients.Carbamazepine has proven antimanic
149
and prophylactic efficacy,
150 and has been traditionally used
in patients who were not sufficiently responding to lithium.
Comparing the prophylactic efficacy of carbamazepine
against lithium,the two most recent studies suggest supe-
riority of lithium treatment.
151,152 However,carbamazepine
appeared in the MAP study to be the better alternative for
atypical manifestations of bipolar disorder,such as rapid
cycling course,frequent recurrence of dysphoric or psy-
chotic mania,or other comorbid psychiatric or neurologi-
cal conditions.
153 In patients not sufficiently responsive to
lithium,addition of carbamazepine can greatly enhance
prophylactic efficacy as shown in a large controlled study.
154
Valproate has nowadays established itself as a first-line
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treatment of acute mania.Superiority over placebo has
been shown in double-blind controlled monotherapy and
add-on studies.
155-158 Compared with lithium, valproate
was especially effective in conditions less responsive to
lithium such as mixed states and a rapid cycling course.
159
For bipolar depression, one small placebo-controlled
study has been published,showing significant effects.
160
The so-far only large-scale randomized maintenance study
comparing valproate against placebo and lithium could
not prove efficacy either for valproate or lithium for the
primary outcome criterion (time to any mood episode).
Further analysis revealed that this was mainly due to a
selection bias,as patients having a benign course of the ill-
ness were overrepresented in the study.Looking for sec-
ondary outcome parameters, however, clinically useful
information was detected,eg,valproate was significantly
better than placebo in preventing new depressive episodes.
In addition,patients who were previously responsive to
valproate when treated for an acute episode also per-
formed better when randomized to valproate maintenance
treatment compared with when randomized to lithium or
placebo. However, reanalyzing this study together with
other,smaller studies,a meta-analysis was able to support
the prophylactic efficacy of valproate.
150
It is of note that phenytoin-exerted antimanic and pro-
phylactic properties,but no antidepressant action,has also
been found in randomized,placebo-controlled studies.
161-163
This has been interpreted as potential proof for an involve-
ment of sodium channel dysregulation in manic states.
However,other mechanisms,such as an as anti-glucocor-
ticoid mechanism,are also possible.
164
Of the new generation of antiepileptic drugs,lamotrigine
in particular is a useful addition to the treatment portfo-
lio.For acute bipolar depression,only one study showed a
positive result in a secondary outcome parameter,
165
whereas three further studies failed to separate it from
placebo.In direct comparison with other treatment modal-
ities,lamotrigine was equal to citalopram,
166 but less effec-
tive than the olanzapine/fluoxetine combination
167 or
tranylcypromine.
168The place of lamotrigine in bipolar dis-
order is obviously in prophylactic treatment.Two double-
blind, randomized maintenance trials over 18 months
proved the efficacy of lamotrigine when compared with
placebo and lithium.
169,170 Both lamotrigine and lithium
were superior to placebo.Looking for differential rates of
relapse,lamotrigine was more effective in preventing new
depressive episodes, whereas lithium was better in pre-
venting manic episodes.
171This finding is also reflected in
a double-blind study where lamotrogine was effective
against acute bipolar depression.
165
For oxcarbazepine,a double-blind study against haloperi-
dol in acute mania showed comparable efficacy.
172 In a
more recent study applying an on-off-on design,however,
oxcarbazepine appeared inefficacious in severely manic
patients,but only in mildly to moderately manic patients.
173
This is in line with a recent randomized,single-blind trial
showing similar efficacy of oxcarbazepine and valproate
in hypomania.
174 In addition, a randomized, controlled
study in adolescent mania failed to separate oxcarbazepine
from placebo;
175 thus,the case for oxcarbazepine in acute
mania is rather weak.As far as bipolar depression and pro-
phylactic treatment are concerned,evidence from method-
ologically rigorous trials is also lacking.
The story of gabapentin in bipolar disorder is largely sim-
ilar:after promising open studies,two add-on studies in
acute mania failed.
176,177 For bipolar depression,open aug-
mentation studies suggest some efficacy in the absence of
controlled data.
178,179As far as long-term treatment is con-
cerned, a recent controlled maintenance study suggests
that maintenance treatment with gabapentin can be ben-
eficial,
180 but larger replication studies are needed.
For levetiracetam,positive open studies in acute mania
181,182
have been reported, but controlled evidence is missing.
More recently, a 31% remission rate was reported in
patients with bipolar disorder who were in the depressed
phase at baseline and who received levetiracetam as add-
on therapy for 8 weeks in an open-label trial.
183 Other
modern antiepileptic drugs,such as tiagabine and retiga-
bine,appear not to be promising in bipolar disorder.
184-189
Topiramate first appeared to be a promising treatment
option in pilot studies; however, five double-blind, ran-
domized studies could not prove efficacy in acute
mania.
190,191 Nevertheless, due to their weight-reducing
effect,topiramate as well as zonisamide,which showed dis-
tinct antimanic and antidepressant properties in open tri-
als,
192-196 may still be options as an add-on treatment in
patients who massively gain weight with established mood
stabilizers.
Personality disorders
Personality disorders accompanied by mood instability
may be a potential target for ACs. In a double-blind,
placebo-controlled crossover trial,carbamazepine signifi-
cantly decreased the severity of behavioral problems in 11
women with borderline personality disorder.
197 Open stud-ies also suggest efficacy of valproate, lamotrigine, and
oxcarbazepine in borderline personality disorder,
198-201 but
controlled studies are missing.Of the newer ACs,the effi-
cacy of topiramate has been tested by one group of inves-
tigators in controlled studies,showing efficacy,especially
on symptoms related to anger,
202-204 but replication of these
positive results from other investigators is still lacking.
Conclusion
Anticonvulsants as a group are today an established
part of the treatment portfolio in many psychiatric con-
ditions,especially in bipolar disorder,anxiety,and pain
disorders. In some instances, their use in psychiatric
indications may even exceed their use in epilepsy.
However, their individual strengths in these different
indications,and the strength of recommendations,may
vary considerably.The story will continue, as new anti-
convulsants such as lacosamide,rufinamide,talampanel,
eslicarbazepine, 10-hydroxy carbazepine, valrocemide,
isovaleramide, brivaracetam, and seletracetam are
potential future candidates for psychiatric indications,
and some of them are already in the process of being
tested in clinical trials. ❏
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La efectividad de los anticonvulsivantes en
los trastornos psiquiátricos
Los medicamentos anticonvulsivantes son amplia-
mente utilizados en indicaciones psiquiátricas. Estas
incluyen principalmente los síndromes de privación
por alcohol y benzodiazepinas, trastornos de ansie-
dad y de pánico, demencia, esquizofrenia, trastor-
nos afectivos, especialmente el trastorno afectivo
bipolar, y en alguna medida en los trastornos de
personalidad. Un área adicional en la que la neu-
rología y la psiquiatría se sobreponen es en las con-
diciones de dolor, en las cuales son útiles algunos
anticonvulsivantes y también medicamentos psi-
quiátricos típicos como los antidepresivos. Desde el
inicio de su empleo en psiquiatría los anticonvulsi-
vantes se han usado también para reducir síntomas
específicos de trastornos psiquiátricos, indepen-
dientemente de su causalidad y de la enfermedad
subyacente; por ejemplo, para la agresión y más
recientemente, para el deterioro cognitivo, y como
se observa en los trastornos afectivos y en la esqui-
zofrenia. Es probable que en psiquiatría aumente
el empleo de los nuevos anticonvulsivantes que
están en desarrollo y que los psiquiatras necesiten
aprender acerca de su eficacia diferencial y perfiles
de seguridad al igual que los neurólogos. 
Efficacité des anticonvulsivants dans les
troubles psychiatriques
Les anticonvulsivants sont largement utilisés en psy-
chiatrie. Le traitement des syndromes de sevrage
d’alcool et de benzodiazépines, des attaques de
panique et des troubles anxieux, les démences, la
schizophrénie, les troubles affectifs, en particulier les
troubles bipolaires, et, d’une certaine façon, les
troubles de la personnalité, font tous partie des indi-
cations psychiatriques. La douleur est un autre
domaine dans lequel la neurologie et la psychiatrie
se chevauchent : certains anticonvulsivants, et aussi
des médicaments typiquement psychiatriques,
comme les antidépresseurs, sont utiles dans certains
cas. Les anticonvulsivants ont aussi, depuis le début
de leur utilisation en psychiatrie, été employés pour
améliorer les symptômes spécifiques des troubles
psychiatriques indépendamment de leur étiologie et
de la maladie sous-jacente. Ces indications peuvent
inclure par exemple, l’agressivité, et, plus récemment
le déficit cognitif, comme les troubles affectifs et la
schizophrénie. Il est probable que leur utilisation en
psychiatrie va augmenter avec les nouveaux anti-
convulsivants actuellement en développement, et
que les psychiatres vont devoir apprendre à
connaître leurs différents profils d’efficacité et de
tolérance comme le font les neurologues.Anticonvulsants in psychiatry  - Grunze Dialogues in Clinical Neuroscience - Vol 10 . No.1 . 2008
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